Medicine & Life Sciences

1. Primary Myelofibrosis 100%
2. Myelodysplastic Syndromes 60%
3. Acute Myeloid Leukemia 52%
4. Survival 50%
5. Karyotype 40%
6. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 38%
7. Mutation 31%
8. venetoclax 24%
9. pomalidomide 19%
10. Cytogenetics 18%
11. Anemia 17%
12. Essential Thrombocythemia 17%
13. Polycythemia Vera 16%
14. Blast Crisis 15%
15. Leukemia 15%
16. Therapeutics 15%
17. Neoplasms 13%
18. 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 13%
19. Systemic Mastocytosis 11%
20. Myeloid Sarcoma 11%
21. High-Throughput Nucleotide Sequencing 11%
22. Induction Chemotherapy 11%
23. Hematologic Neoplasms 10%
24. Azacitidine 10%
25. Platelet Count 10%
26. Decitabine 10%
27. Thrombocytosis 10%
28. N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide 9%
29. Bone Marrow 9%
30. Second Primary Neoplasms 8%
31. midostaurin 8%
32. Peripheral Nervous System Diseases 8%
33. Elderly 8%
34. sapacitabine 8%
35. imetelstat 7%
36. Fedratinib 7%
37. Transplants 7%
38. Splenomegaly 7%
39. Thrombocytopenia 7%
40. Monosomy Chromosome 7 6%
41. Survival Rate 6%
42. anagrelide 6%
43. Cladribine 6%
44. Acute Promyelocytic Leukemia 6%
45. Chromosome 5q Deletion Syndrome 6%
46. Hemoglobins 6%
47. Leukemia, Myelomonocytic, Chronic 6%
48. Protein-Tyrosine Kinases 6%
49. Panobinostat 6%
50. Hematopoietic Stem Cells 6%